Jump to content

Genedata and Insilico Biotechnology Integrate Industrial Biotechnology Platforms

Integrative bioinformatics platform will streamline and accelerate production strain optimization for fermentation-based applications

September 19, 2012
Munich, Germany

Genedata, a leading provider of advanced software solutions for industrial biotechnology, drug discovery and life science research, and Insilico Biotechnology, a premier provider of advanced solutions for genome-scale simulations, today announced the integration of their technologies, which creates an end-to-end platform for industrial biotechnology research. The platform integrates Genedata Selector™ for comprehensive genome management and data analysis with Insilico Discovery™ simulation software. SysEnCor, a German research consortium, will use the integrated platform to analyze the energy metabolism of Corynebacterium glutamicum, a key organism for bioprocessed amino acids used in food and feed production.

“By integrating our respective platforms, Genedata and Insilico Biotechnology offer a solution that empowers companies to combine quantitative biotechnology with hypothesis generation with experimental validation,” said Klaus Mauch, CEO of Insilico Biotechnology. “The integration of Insilico Biotechnology and Genedata Selector software paves the way for innovative strain optimization and fermentation processes in areas such as feed and food additives, care specialties, and therapeutic precursors,” noted Dr. Othmar Pfannes, CEO of Genedata.
SysEnCor Innovates Strain Development
Cost factors in large-scale biotechnological production processes include feedstock, the efficiency of microorganism conversion to product, and the ability to quickly obtain high yields. C. glutamicum optimization requires a comprehensive understanding of genetic make-up, functional characterization of macromolecules and their interactions, and identification of underlying metabolic and regulatory networks controlling strain growth and productivity. SysEnCor applies advanced systems biotechnology to quantify, understand and design energy metabolism in developing novel production strains.

Co-funded by the German Federal Ministry of Education and Research, SysEnCor is comprised of Evonik Degussa, Genedata, Insilico Biotechnology and seven academic institutions. Using mathematical modeling and simulation, high-throughput molecular profiling, and innovative data analysis for next-generation sequencing data, SysEnCor is pioneering stress-tolerant and efficient microbial strains for the synthesis of amino acids such as arginine and histidine. Collaborating with SysEnCor and its industrial partners, Genedata is integrating Genedata Selector—the only system for complete mapping of all omics and pathway data—with Insilico Discovery, the only system for obtaining fluxome data and dynamic network simulations. The resulting platform will significantly enhance genome-wide dynamic models of C. glutamicum while streamlining and accelerating strain development cycles.

“Integrating Insilico Discovery software and Genedata Selector provides an organism-agnostic and comprehensive software platform that handles everything from strain genome information management to bioprocess modeling,” continued Dr. Pfannes. “Our collaboration with Insilico Biotechnology and involvement with SysEnCor reflects our long-standing and continuously expanding presence in the industrial biotech sector, and underscores the companies’ commitment to innovative industrial biotech solutions.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube


Rebecca Finck
Public Relations


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

By integrating our respective platforms, Genedata and Insilico Biotechnology offer a solution that empowers companies to combine quantitative biotechnology with hypothesis generation with experimental validation

Klaus Mauch